Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1051-1058. doi: 10.1136/jnnp-2018-320165. Epub 2019 Jun 13.
Impairment of mental well-being (anxiety, depression, stress) is common among people with multiple sclerosis (PwMS). Treatment options are limited, particularly for anxiety. The aim of this study was to update our previous systematic review (2014) and evaluate via meta-analysis the efficacy of mindfulness-based interventions (MBIs) for improving mental well-being in PwMS.
Systematic searches for eligible randomised controlled trials (RCTs) were carried out in seven major databases (November 2017, July 2018), using medical subject headings and key words. Studies were screened, data extracted, quality appraised and analysed by two independent reviewers, using predefined criteria. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Mental well-being was the primary outcome. Random effects model meta-analysis was performed, with effect size reported as standardised mean difference (SMD).
Twelve RCTs including 744 PwMS were eligible for inclusion in the systematic review, eight had data extractable for meta-analysis; n=635. Ethnicity, socioeconomic status, comorbidity and disability were inconsistently reported. MBIs varied from manualised to tailored versions, lasting 6-9 weeks, delivered individually and via groups, both in person and online. Overall SMD for mental well-being (eight studies) was 0.40 (0.28-0.53), p<0.01, I=28%; against active comparators only (three studies) SMD was 0.17 (0.01-0.32), p<0.05, I =0%. Only three adverse events were reported.
MBIs are effective at improving mental well-being in PwMS. More research is needed regarding optimal delivery method, cost-effectiveness and comparative-effectiveness.
CRD42018093171.
精神健康受损(焦虑、抑郁、压力)在多发性硬化症患者(PwMS)中很常见。治疗选择有限,特别是对于焦虑症。本研究旨在更新我们之前的系统评价(2014 年),并通过荟萃分析评估基于正念的干预(MBIs)对改善 PwMS 精神健康的疗效。
在七个主要数据库(2017 年 11 月、2018 年 7 月)中进行了针对合格随机对照试验(RCT)的系统搜索,使用医学主题词和关键词。由两名独立评审员进行研究筛选、数据提取、质量评估和分析,使用预定标准。使用 Cochrane 协作风险偏倚工具评估研究质量。精神健康是主要结局。采用随机效应模型进行荟萃分析,报告效应大小为标准化均数差(SMD)。
共有 12 项 RCT 纳入了系统评价,其中包括 744 名 PwMS,其中 8 项研究的数据可用于荟萃分析;n=635。种族、社会经济地位、合并症和残疾的报告不一致。MBIs 从手册化到定制版本不等,持续 6-9 周,以个人和小组的形式进行,包括面对面和在线两种方式。针对精神健康的总体 SMD(八项研究)为 0.40(0.28-0.53),p<0.01,I=28%;仅针对活性对照(三项研究)的 SMD 为 0.17(0.01-0.32),p<0.05,I=0%。仅报告了三项不良事件。
MBIs 对改善 PwMS 的精神健康有效。需要更多的研究来确定最佳的交付方法、成本效益和比较效果。
PROSPERO 注册号:CRD42018093171。